Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (106)
  • Autophagy
    (32)
  • EGFR
    (23)
  • Akt
    (16)
  • NF-κB
    (16)
  • PI3K
    (15)
  • PROTACs
    (14)
  • COX
    (13)
  • DNA/RNA Synthesis
    (13)
  • Others
    (451)
Filter
Search Result
Results for "

tumor cells

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    1039
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    13
    TargetMol | Compound_Libraries
  • Peptide Products
    50
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    47
    TargetMol | Inhibitory_Antibodies
  • Dye Reagents
    7
    TargetMol | Dye_Reagents
  • PROTAC Products
    29
    TargetMol | PROTAC
  • Natural Products
    139
    TargetMol | Natural_Products
  • Recombinant Protein
    394
    TargetMol | Recombinant_Protein
  • Isotope Products
    10
    TargetMol | Isotope_Products
  • Cell Research
    13
    TargetMol | Inhibitors_Agonists
Gefitinib
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Erastin
T1765571203-78-6
Erastin is an iron death activator that acts on the mitochondrial VDAC in a ROS- and iron-dependent manner. Erastin has anti-tumor activity and acts selectively on tumor cells with RAS-carcinogenic mutations.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
MRTX1133
T93032621928-55-8In house
MRTX1133 is a KRAS G12D inhibitor (KD=0.2 pM) that is potent, selective, and non-covalent. MRTX1133 exhibits inhibitory activity against KRAS G12D-mutated tumors, but not against KRAS wild-type tumors.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Fedratinib
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Quizartinib
AC220
T2066950769-58-1
Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Ro-3306
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Osimertinib
Mereletinib, AZD-9291
T24901421373-65-0
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Salidroside
Rhodioloside
T271710338-51-9
Salidroside is a bioactive phenolic glycoside compound isolated from Rhodiola rosea and is a prolyl endopeptidase inhibitor. Salidroside can alleviate cachexia symptoms in a tumor cachexia mouse model by activating mTOR signaling and protect dopaminergic neurons by enhancing PINK1 Parkin-mediated mitochondrial autophagy. Salidroside can also inhibit the growth of cancer cells by regulating the CDK4-cyclin D1 pathway to block the G1 phase and or regulating the Cdc2-cyclin B1 pathway to block the G2 phase.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Ivosidenib
AG-120
T36171448347-49-6
Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity. It specifically inhibits a mutated form of IDH1 in the cytoplasm, preventing the formation of the oncometabolite 2-hydroxyglutarate (2 hG), which may induce cellular differentiation and inhibit cellular proliferation in IDH1-expressing tumor cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
RSL3
RSL3 1S, 1S,3R-RSL3
T36461219810-16-8
RSL3 (RSL3 1S) is an inhibitor of GPX4, and inhibits system xc- that blocks GSH synthesis (IC50=100 nM). RSL3 is a VDAC-independent activator of ferroptosis that is selective for tumor cells carrying oncogenic RAS.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
afmk
Formyl-N-acetyl-5-methoxykynurenamine, Acetyl-N-formyl-5-methoxykynurenamine
T4134552450-38-1In house
AFMK (Formyl-N-acetyl-5-methoxykynurenamine) is an active metabolite of Melatonin with antioxidant and free radical scavenging activity. AFMK is a modulator of apoptosis and improves the anti-tumor effect of Gemcitabine in PANC-1 cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
RP-6306
T608892719793-90-3
Lunresertib (RP-6306) is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 14 nM. Lunresertib (RP-6306) inhibits the growth of CCNE1-amplified tumor cells in several preclinical xenograft models.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Hot
Elesclomol
STA-4783
T6170488832-69-5
Elesclomol (STA-4783) is an oxidative stress inducer and a highly lipophilic copper ion carrier. Elesclomol induces apoptosis in tumor cells and is used in copper death related studies. Elesclomol also inhibits FDX1-mediated Fe-S cluster biosynthesis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Ixabepilone
Ixempra, BMS 247550-1, BMS 247550, Azaepothilone B
T6864219989-84-1
Ixabepilone (Azaepothilone B) is an orally bioavailable microtubule inhibitor. It binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Omaveloxolone
RTA-408
T69191474034-05-3
Omaveloxolone (RTA-408) (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Amivantamab
JNJ-61186372, JNJ61186372, JNJ 61186372
T771102171511-58-1
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Hot
Adagrasib
MRTX849
T83692326521-71-3
Adagrasib (MRTX849) is an orally active and selective covalent inhibitor of KRAS G12C. Adagrasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Adagrasib exhibits inhibitory activity against KRAS G12C mutant tumors.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Atezolizumab
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Antitumor agent-19
T103412379727-90-7In house
Antitumor agent-19 is a modulator of tumor-associated macrophages with EC50s of 17.18 μM and 18.87 μM in the RAW 264.7 cells and the BMDM cells.
  • Inquiry Price
6-8 weeks
Size
QTY
Cevipabulin
TTI-237
T10772849550-05-6In house
Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
  • Inquiry Price
6-8 weeks
Size
QTY
CHK1-IN-4 hydrochloride
CHK1-IN-4 hydrochloride(2120398-41-4 Free base)
T10792L In house
CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1). CHK1-IN-4 hydrochloride potently inhibits chk1 phosphorylation in the tumor cells. CHK1-IN-4 hydrochloride has anti-tumor activity.
  • Inquiry Price
Size
QTY
DMAPT
Dimethylamino Parthenolide
T11060870677-05-7In house
DMAPT (Dimethylamino Parthenolide) is an orally active NF-κB inhibitor and a Parthenolide (PTL) analogue with an LD50 value of 1.7 μM for primary acute myeloid leukemia cells. It has potential anti-tumor and anti-metastatic effects.
  • Inquiry Price
Size
QTY
HLY78
4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine
T11571854847-61-3In house
HLY78 (4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine) targets the DIX domain of Axin, is an activator of the Wnt β-catenin signaling pathway and can enhance Axin-LRP6 binding to promote Wnt signaling.
  • Inquiry Price
Size
QTY
OTS186935 FA
OTS186935 FA(2093400-18-9 Free base)
T12344L1 In house
OTS186935 FA is a protein methyltransferase SUV39H2 inhibitor.OTS186935 FA inhibits tumor growth in MDA-MB-231 breast cancer cells and A549 lung cancer cells.
  • Inquiry Price
Size
QTY